 Home > Biochemistry News > Biotechnology News > Boan Biotech brings CD3+ T-cell Engager patent platform and CEA/CD3 research results to the World Bispecific Antibody Summit

Boan Biotech brings CD3+ T-cell Engager patent platform and CEA/CD3 research results to the World Bispecific Antibody Summit

 Last Update: 2021-09-28
 Source: Internet
 Author: User

Tags

treat iron toxicity

thyroglobulin antibody high

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Boston, September 26, 2021/PRNewswire/ - Luye Pharmaceutical Group's holding subsidiary Boan Bio will present its CD3+ T- in the form of an oral report at the World Bispecific Summit 2021 (World Bispecific Summit 2021) The cell Engager patented technology platform and the first research project based on this platform-CEA/CD3 new bispecific antibody preclinical research results

The World Bispecific Antibody Summit aims to promote the development of bispecific antibody therapy.

The key information of Boan Bio's research report at this summit is as follows:

Report topic: Improve the safety of bispecific antibodies by optimizing the CD3+T-cell Engager technology platform

Sub-venue category: T cell-based tumor treatment methods

Report time: October 1, 2021

Research Background:

The CD3+T-cell Engager bispecific antibody is currently one of the most promising dual-antibody drugs that can effectively treat cancer, but it faces dose limitations during the development process, has fatal cytokine storm toxicity, and has poor efficacy , There are many challenges such as toxicity risks due to off-target effects

The CEA/CD3 bispecific antibody (BA1202) is the first drug under research developed by Boan Biological based on its bispecific T-cell Engager technology platform

In addition to BA1202, Boan Bio has a number of bispecific antibody drugs under research with similar optimized structures and low affinity for CD3

About Boan Bio

Boan Biologics, a holding subsidiary of Luye Pharmaceutical Group, is a comprehensive biopharmaceutical company specializing in the development, production and commercialization of therapeutic antibodies, focusing on tumors, autoimmune, pain and endocrine diseases

Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production

Source: Luye Pharma

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.